QV Investors Inc. Sells 5,980 Shares of Solventum Corporation $SOLV

QV Investors Inc. cut its stake in Solventum Corporation (NYSE:SOLV) by 2.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 218,692 shares of the company’s stock after selling 5,980 shares during the period. Solventum comprises approximately 1.3% of QV Investors Inc.’s portfolio, making the stock its 28th largest position. QV Investors Inc.’s holdings in Solventum were worth $16,872,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Independent Franchise Partners LLP raised its position in Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after purchasing an additional 2,456,451 shares in the last quarter. State Street Corp boosted its holdings in shares of Solventum by 2.0% in the 4th quarter. State Street Corp now owns 6,344,761 shares of the company’s stock worth $502,759,000 after purchasing an additional 124,490 shares in the last quarter. Boston Partners increased its position in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Solventum by 20.0% during the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after purchasing an additional 763,308 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Solventum by 3.4% during the 4th quarter. Invesco Ltd. now owns 2,930,010 shares of the company’s stock valued at $232,174,000 after purchasing an additional 96,236 shares during the last quarter.

Analyst Ratings Changes

SOLV has been the subject of a number of recent research reports. Piper Sandler boosted their target price on Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. BMO Capital Markets started coverage on shares of Solventum in a research report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price target on the stock. Mizuho set a $113.00 price target on shares of Solventum in a research note on Thursday, August 6th. BTIG Research boosted their price objective on shares of Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Wedbush upped their price objective on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Solventum presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.64.

Solventum Stock Down 0.1%

SOLV opened at $91.02 on Monday. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $92.71. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The business’s 50-day moving average price is $82.46 and its 200-day moving average price is $75.53. The company has a market cap of $15.49 billion, a P/E ratio of 11.13, a P/E/G ratio of 1.17 and a beta of 0.60.

Solventum (NYSE:SOLV) last issued its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same period in the prior year, the business posted $1.69 EPS. Solventum’s quarterly revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities analysts expect that Solventum Corporation will post 7.22 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.